| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1010: Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria |
|
Medicine details |
|
| Medicine name | danicopan (Voydeya®) |
| Formulation | 50 mg film-coated tablets, 100 mg film-coated tablets |
| Reference number | 4537 |
| Indication | As an add-on treatment to a C5 inhibitor for treating extravascular haemolysis in adults with paroxysmal nocturnal haemoglobinuria |
| Company | Alexion Europe |
| BNF chapter | Nutrition & blood |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 16/09/2024 |
| NICE guidance | TA1010: Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria |